Arterial Embolism After Catheter Ablation of Atrial Fibrillation. ATRIAL FIBRILLATION

Launched by HOSPITAL UNIVERSITARIO LA PAZ · Nov 11, 2023

Keywords

ClinConnect Summary

The EMBOL-AF trial is a study that looks at the occurrence of blood clots in patients who have undergone a treatment called catheter ablation for atrial fibrillation, a type of irregular heartbeat. Specifically, the study focuses on understanding how often these clots happen, especially in the brain, which can lead to strokes or mini-strokes (called TIAs). Researchers will collect information from various medical centers about patients who experienced these events within the last five years to learn more about their management and outcomes.

To be eligible for this study, participants must have experienced a blood clot event like a stroke or TIA within seven days of their ablation procedure, which has to be linked to the treatment. The study is open to all adults, and participants can expect to contribute their medical information, which will help improve understanding of the risks associated with this procedure. It's important to note that if the blood clot was caused by another type of surgery or procedure, that case would not be included in this study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Systemic arterial embolism (stroke, TIA or any other symptomatic event) after catheter ablation for AF or left atrial macroreentrant atrial tachycardia or left atrial flutter that have occurred between 1st january 2017 and 31st july 2023.
• • The embolic event must be associated with the ablation procedure, therefore, it must have occurred during the procedure or during the first 7 days after it, during hospital stay or after discharge.
• Exclusion Criteria:
• • The embolic event that occurred during the first 7 days after the ablation procedure can be undoubtedly attributed to other causes, such as surgery (cardiac, aortic or carotidal) or percutaneous interventions (coronary, cardiac structural, aortic or carotidal).